Association of Glycated Albumin/Glycosylated Hemoglobin Ratio with Blood Glucose Fluctuation and Long-Term Blood Glucose Control in Patients with Type 2 Diabetes Mellitus

Wang, Bairong; Yao, Jun-Teng; Zheng, Hui; Li, Quanmin

doi:10.2147/dmso.s297730

Cited by 14 publications

(11 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have found that CSII can better control blood glucose than MDI [ 13 ]. HbA1c is an essential indicator for evaluating blood glucose control and predicting the occurrence and development of chronic complications of diabetes, and it can effectively reflect the average blood glucose level in 2∼3 months [ 14 ]. In the present study, the HbA1c level was markedly lower in groups B and D than in group A, indicating the insulin pump's relatively good hypoglycemic effect.…”

Section: Discussionmentioning

confidence: 99%

Comparison of the Efficacy of Different Insulin Administration and Blood Glucose Monitoring Methods in the Treatment of Type 1 Diabetes Mellitus in Children

Deng

Chen

Wang

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. To compare the clinical efficacy of different insulin administration methods and blood glucose monitoring methods in treating type 1 diabetes mellitus in children. Methods. Patients were divided into four groups: multiple daily injection (MDI) + fingertip blood glucose detection, continuous subcutaneous insulin infusion (CSII) + fingertip blood glucose detection, MDI + continuous glucose monitoring system (CGMS), and CSII + CGMS. After six months of treatment, followed by telephone and at least once a month in an outpatient clinic, insulin doses were adjusted according to the children’s blood glucose levels. Blood glucose control and the daily dose of insulin were compared among the four groups after treatment, and the incidence of hypoglycemia in each group was recorded during the treatment. We also compare the incidence of the adverse event among the four groups. Results. 6 months later, the levels of HbA1c, FBG, and two h PG in each group were lower than those before treatment. There were significant differences in HbA1c, two h PG, and the daily insulin dose among the four groups. There were differences in the frequency of hypoglycemia among all the groups. The frequency of hypoglycemia in groups C and D was lower than in group A. Conclusions. CSII was better than MDI, and the blood glucose monitoring effect of CGMS was better than the fingertip blood glucose detection. The patients treated with CSII combined with CGMS had the best clinical efficacy. The patients treated with CSII combined with CGMS had the lowest adverse events incidence.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of the Efficacy of Different Insulin Administration and Blood Glucose Monitoring Methods in the Treatment of Type 1 Diabetes Mellitus in Children

Deng

Chen

Wang

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…In addition, we also found that the FC-P and 2hC-P levels of the patients in the experimental group were significantly higher than those in the control group after 3 and 6 months of treatment. The HbA1c was reported closely related to the MAGE and islet function in patients with T2DM ( 31 ). Our study found that TIR was significantly related to the islet function adjusting for age, sex, BMI, diabetes duration, blood pressure, lipid profile, and HbA1c.…”

Section: Discussionmentioning

confidence: 99%

Effects of dulaglutide combined with insulin degludec on glucose fluctuations and appetite in type 2 diabetes

et al. 2023

View full text Add to dashboard Cite

IntroductionThe aim of this study was to describe appetite and glucose fluctuation in type 2 diabetes mellitus patients initiating treatment with dulaglutide combined with insulin degludec.MethodsThis retrospective study of patients identified adults starting treatment with once-weekly (QW) dulaglutide combined with insulin degludec (experimental group) or insulin degludec alone (control group). Patients were followed for up to 6 months from treatment initiation. The clinical characteristics of patients, treatment patterns, CGM data, and appetite scores were obtained for the two groups.ResultsA total of 236 patients were included in this study. SDBG, MAGE, LAGE, and PPGE of the experimental group were lower than the control group’s (P < 0.05). The proportions of patients achieving a time in range (TIR) of ≥70% in the experimental group were higher than in the control group, with 43% and 10% on the second day, 88% and 47% on the fourth day, 95% and 47% on the seventh day, and 100% and 67% on the tenth day, respectively. Significant associations existed between TIR and the prevalence of islet function. At six months, 89.2% of patients in the experimental group were still using dulaglutide. Appetite decreased significantly at 1 week and increased at 3 months after treatment with dulaglutide.ConclusionDulaglutide combined with insulin degludec significantly reduces glucose fluctuations in patients with type 2 diabetes mellitus and improves the TIR rate. However, the treatment on appetite could decrease in the first three months.

show abstract

“…Therefore, developing an index that can be used in the clinic to rapidly assess glycemic variability for the diabetic population is needed. Previous studies found that 1,5-anhydroglucitol ( r ² = 0.77, p = 0.03) and the ratio of glycosylated albumin (GA) to HbA1c (β = 0.061, p = 0.004), both were independently and positively correlated with the Mean Amplitude of Glycemic Excursions [ 9 , 10 ]. However, the sensitivity and specificity of GA/HbA1c and 1,5-anhydroglucitol for use as indicators to screen glycemic variability has not been investigated.…”

Section: Introductionmentioning

confidence: 99%

Glycemic dispersion: a new index for screening high glycemic variability

Shi

Liu

et al. 2023

Diabetol Metab Syndr

View full text Add to dashboard Cite

Objective For patients with diabetes, high-frequency and -amplitude glycemic variability may be more harmful than continuous hyperglycemia; however, there is still a lack of screening indicators that can quickly and easily assess the level of glycemic variability. The aim of this study was to investigate whether the glycemic dispersion index is effective for screening high glycemic variability. Methods A total of 170 diabetes patients hospitalized in the Sixth Affiliated Hospital of Kunming Medical University were included in this study. After admission, the fasting plasma glucose, 2-hour postprandial plasma glucose, and glycosylated hemoglobin A1c were measured. The peripheral capillary blood glucose was measured seven times in 24 h, before and after each of three meals and before bedtime. The standard deviation of the seven peripheral blood glucose values was calculated, and a standard deviation of > 2.0 was used as the threshold of high glycemic variability. The glycemic dispersion index was calculated and its diagnostic efficacy for high glycemic variability was determined by the Mann–Whitney U test, receiver operating characteristic (ROC) curve and, Pearson correlation analysis. Results The glycemic dispersion index of patients with high glycemic variability was significantly higher than that of those with low glycemic variability (p < 0.01). The best cutoff value of the glycemic dispersion index for screening high glycemic variability was 4.21. The area under the curve (AUC) was 0.901 (95% CI: 0.856–0.945) and had a sensitivity of 0.781 and specificity of 0.905. It was correlated with the standard deviation of blood glucose values (r = 0.813, p < 0.01). Conclusions The glycemic dispersion index had good sensitivity and specificity for screening high glycemic variability. It was significantly associated with the standard deviation of blood glucose concentration and is simple and easy to calculate. It was an effective screening indicator of high glycemic variability.

show abstract

Association of Glycated Albumin/Glycosylated Hemoglobin Ratio with Blood Glucose Fluctuation and Long-Term Blood Glucose Control in Patients with Type 2 Diabetes Mellitus

Cited by 14 publications

References 26 publications

Comparison of the Efficacy of Different Insulin Administration and Blood Glucose Monitoring Methods in the Treatment of Type 1 Diabetes Mellitus in Children

Comparison of the Efficacy of Different Insulin Administration and Blood Glucose Monitoring Methods in the Treatment of Type 1 Diabetes Mellitus in Children

Effects of dulaglutide combined with insulin degludec on glucose fluctuations and appetite in type 2 diabetes

Glycemic dispersion: a new index for screening high glycemic variability

Contact Info

Product

Resources

About